PHAT Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of -60.55% compared to Phathom Pharmaceuticals, Inc.'s net margin of -255.85%. Phathom Pharmaceuticals, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Phathom Pharmaceuticals, Inc. has a consensus price target of $22.90, signalling upside risk potential of 67.52%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -54.3%. Given that Phathom Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Phathom Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Phathom Pharmaceuticals, Inc. has a beta of 0.484, which suggesting that the stock is 51.57% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.

Phathom Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Phathom Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Phathom Pharmaceuticals, Inc. quarterly revenues are $49.5M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Phathom Pharmaceuticals, Inc.'s net income of -$30M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Phathom Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 3.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals, Inc. is 6.71x versus 3.61x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -60.55% compared to Phathom Pharmaceuticals, Inc.'s net margin of --. Phathom Pharmaceuticals, Inc.'s return on equity of -- beat Palatin Technologies's return on equity of --.

Phathom Pharmaceuticals, Inc. has a consensus price target of $22.90, signalling upside risk potential of 67.52%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Phathom Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than Phathom Pharmaceuticals, Inc..

Phathom Pharmaceuticals, Inc. has a beta of 0.484, which suggesting that the stock is 51.57% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Phathom Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Phathom Pharmaceuticals, Inc. quarterly revenues are $49.5M, which are larger than Palatin Technologies quarterly revenues of --. Phathom Pharmaceuticals, Inc.'s net income of -$30M is higher than Palatin Technologies's net income of --. Notably, Phathom Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals, Inc. is 6.71x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -60.55% compared to Phathom Pharmaceuticals, Inc.'s net margin of --. Phathom Pharmaceuticals, Inc.'s return on equity of -- beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Phathom Pharmaceuticals, Inc. has a consensus price target of $22.90, signalling upside risk potential of 67.52%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3788.89%. Given that Theriva Biologics, Inc. has higher upside potential than Phathom Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Phathom Pharmaceuticals, Inc..

Phathom Pharmaceuticals, Inc. has a beta of 0.484, which suggesting that the stock is 51.57% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.

Phathom Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Phathom Pharmaceuticals, Inc. quarterly revenues are $49.5M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Phathom Pharmaceuticals, Inc.'s net income of -$30M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Phathom Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals, Inc. is 6.71x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of -60.55% compared to Phathom Pharmaceuticals, Inc.'s net margin of -40.15%. Phathom Pharmaceuticals, Inc.'s return on equity of -- beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.

Phathom Pharmaceuticals, Inc. has a consensus price target of $22.90, signalling upside risk potential of 67.52%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $13.63 which suggests that it could grow by 80.7%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Phathom Pharmaceuticals, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Phathom Pharmaceuticals, Inc..

Phathom Pharmaceuticals, Inc. has a beta of 0.484, which suggesting that the stock is 51.57% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.647%.

Phathom Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Phathom Pharmaceuticals, Inc. quarterly revenues are $49.5M, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Phathom Pharmaceuticals, Inc.'s net income of -$30M is lower than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Phathom Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals, Inc. is 6.71x versus 2.09x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.